司美替尼在华获批新适应症,用于治疗1型神经纤维瘤病

新京报
Mar 31

新京报讯(记者王卡拉)3月30日,阿斯利康宣布,中国国家药品监督管理局已正式批准选择性、口服MEK抑制剂硫酸氢司美替尼胶囊(商品名:科赛优)新适应症,用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤(PN)的1型神经纤维瘤病(NF1)儿童及成人患者的治疗。  NF是一种罕见的进展性、遗传性疾病,多在儿童早期确诊,病程常延续至成年,可导致全身多系统受累。多达50%的NF1患者会出现丛状神经纤维瘤...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10